Thailand. Daiichi Sankyo and Ranbaxy to leverage synergies in Thailand

Tokyo, Japan and Gurgaon, India, January 16, 2013: Daiichi Sankyo Company, Limited (Daiichi Sankyo) and Ranbaxy Laboratories Limited (Ranbaxy) today announced their intention to integrate their business operations in Thailand, to leverage and maximize the synergies of the Hybrid Business Model, which is expected to commence business on April 1, 2013.

The planned integration of operations will provide a strong foundation for future Daiichi Sankyo Group business expansion in Thailand. The development will be mutually beneficial to Ranbaxy and Daiichi Sankyo. It is expected to enhance their competitiveness while offering both innovative and affordable, high quality generic medicines to the people of Thailand as well as generate cost synergies for both companies.

Under this strategy, Daiichi Sankyo and Ranbaxy would integrate the management of Daiichi Sankyo’s subsidiary in Thailand, Daiichi Sankyo (Thailand) Ltd. (DSTH) and Ranbaxy’s Thailand subsidiary, Ranbaxy Unichem Co., Ltd. (RUCL). The new representative of the proposed integrated entity will be Suthas Thongprasert, who presently heads DSTH.

The pharmaceutical market in Thailand is the 2nd largest among ASEAN countries, and DSTH has built its presence mainly by targeting healthcare facilities through innovative pharmaceuticals. The company was founded in 1994 and had sales of JPY 1.2 billion yen in FY 2011. On the other hand, RUCL markets generic medicines focusing on primary healthcare and pharmacies. RUCL was established in 1983 and had sales of US$ 14 million in CY 2011.

About Ranbaxy Laboratories Limited Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.

About Daiichi Sankyo The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Source: PharmaLive